Boswellia
Boswellia serrata · Shallaki (Indian frankincense)
Frankincense resin with solid osteoarthritis evidence.
Evidence tier
Moderate
Research weight
Citations
18 verified / 18
Classification
Ayurvedic
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.
What is Boswellia?
Boswellia (Boswellia serrata · Shallaki (Indian frankincense)) is an Ayurvedic herb used for reduced osteoarthritis pain & stiffness. NutriDex grades the human evidence as Moderate. Boswellia (Indian frankincense) yields boswellic acids that inhibit the inflammatory enzyme 5-lipoxygenase. A meta-analysis of seven trials found it reduces osteoarthritis pain and stiffness and improves function, with benefit typically emerging over about four weeks and a side-effect profile gentler than NSAIDs. It is one of the better-supported Ayurvedic herbs for a specific condition.
Purported Benefits
✓Reduced osteoarthritis pain & stiffness
✓Anti-inflammatory (5-LOX inhibition)
✓Improved joint function
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Osteoarthritis pain & stiffnessMultiple meta-analyses (e.g. 7 RCTs, n=545) show significant pain/stiffness reduction, though one 2024 pool was non-significant from high heterogeneity and quality is rated low. | Moderate | ↑ benefit · moderate | 5 |
| Joint / physical functionMeta-analyses report improved WOMAC function and Lequesne scores; benefit typically requires >=4 weeks of treatment. | Moderate | ↑ benefit · moderate | 4 |
| 5-LOX inhibition / anti-inflammatoryMechanism is preclinical, though one OA RCT showed lowered hs-CRP, IL-6 and TNF-alpha with a combination product. | Preliminary | ↑ benefit | 2 |
| Crohn's disease remission maintenance52-week RCT (n=82) failed to maintain remission better than placebo (~60% vs ~55%, p=0.85). | Moderate | — no effect · negligible | 1 |
| Bronchial asthma symptomsA single small 1998 RCT (n=80) improved symptoms/FEV1 in 70% vs 27% placebo; old and unreplicated. | Preliminary | ↑ benefit · moderate | 1 |
| Radiation-induced cerebral edemaOne RCT (n=44) reduced edema >75% in 60% vs 26% placebo; single small trial in a narrow population. | Preliminary | ↑ benefit · large | 1 |
Dosing & Compounds
Typical Dose
100–250 mg/day of a standardized extract (e.g. AKBA-enriched), for ≥4 weeks.
Active Compounds
Safety & Cautions
Generally well tolerated; mild GI upset possible. May interact with anti-inflammatory or immune drugs. Limited pregnancy data — avoid. Educational only — always check with your doctor or pharmacist before combining Boswellia with any medicine.
Key Studies ★ 18 studies
systematic review and meta-analysis
Boswellia oleogum resin meta-analysis 2024
✓ Source
A systematic review and meta-analysis of randomized trials found Boswellia oleogum resin extracts significantly reduced pain and improved function in knee osteoarthritis versus control.
systematic review and meta-analysis
Aflapin sub-group meta-analysis 2024
✓ PubMed
A systematic review and sub-group meta-analysis of 9 RCTs (712 participants) found Boswellia serrata extract reduced osteoarthritis pain and stiffness, with the standardized Aflapin extract showing the largest effect.
Meta-analysis
Sengupta 2025 (network meta-analysis)
✓ PubMed
Systematic review and network meta-analysis of 20 RCTs (n=1,633, searched through March 2025) found modified Boswellia serrata formulations significantly improved WOMAC pain, stiffness, and knee function in mild-to-moderate knee osteoarthritis versus comparators, with no significant difference in adverse events.
Meta-analysis
Dalmonte et al. (2024)
✓ PubMed
Systematic review/meta-analysis of 13 RCTs (850 WOMAC, 1,185 VAS patients) on Boswellia oleogum-resin extracts in knee OA: overall pooled effect was non-significant due to high heterogeneity (WOMAC p=0.087; VAS p=0.397), but subgroup analysis vs placebo and meta-regression showed a significant reduction in WOMAC scores favoring Boswellia.
Meta-analysis
Yu 2020 meta-analysis
✓ Full text
Across 7 trials, Boswellia reduced OA pain and stiffness vs control.
Meta-analysis
Yu et al. (2020)
✓ PubMed
Meta-analysis of 7 RCTs (545 OA patients): Boswellia/extract significantly reduced pain (VAS WMD -8.33, 95% CI -11.19 to -5.46; WOMAC pain WMD -14.22, 95% CI -22.34 to -6.09), stiffness (WMD -10.04), and improved function (WOMAC function WMD -10.75; Lequesne WMD -2.27) vs control; benefit required at least 4 weeks of treatment.
Meta-analysis
Bannuru et al. (2018)
✓ PubMed
Tufts systematic review/meta-analysis of 11 RCTs (N=1,009): both Boswellia and curcuminoid formulations were significantly more effective than placebo for pain relief and functional improvement in knee OA, with no significant difference in safety outcomes; authors caution overall evidence quality was low.
randomized controlled trial
Saxena 2024 RCT (3-arm)
✓ PubMed
In a double-blind 3-arm RCT (n=105 knee OA), standardized Boswellia serrata extract reduced VAS pain ~45-62% and improved WOMAC-total ~69-74% over 90 days vs placebo, with benefit seen within 5 days.
randomized controlled trial
Boswellia + Apium graveolens RCT 2025
✓ Full text
In a randomized double-blind multicenter trial (n=62 knee OA), a Boswellia serrata gum-resin (300 mg) plus celery seed extract significantly reduced WOMAC and VAS pain, stiffness and swelling vs placebo over 90 days.
randomized controlled trial
BOSMAX RCT 2025
✓ PubMed
A randomized, placebo-controlled, double-blind study found Boswellia serrata (BOSMAX) improved pain and function in patients with early knee osteoarthritis vs placebo.
RCT
Pharmaceutical Research 2025 RCT
✓ PubMed
Randomized, double-blind, multicenter, placebo-controlled RCT (n=62, 90 days) of Boswellia serrata gum resin (300 mg) plus Apium graveolens seed extract (250 mg) twice daily reduced WOMAC pain/stiffness/swelling and lowered hs-CRP, IL-6, TNF-alpha, and ESR versus placebo.
Agency / regulator
NCCIH (NIH) Boswellia
✓ Source
NIH/NCCIH states that although some studies suggest oral Boswellia may reduce osteoarthritis inflammation and pain, there is not enough high-quality evidence to conclude it is useful for any health condition, and little safety data exists for most boswellia products.
rct
Kirste 2011 cerebral edema RCT
✓ PubMed
In a prospective, randomized, placebo-controlled, double-blind trial (n=44 patients irradiated for brain tumors), Boswellia serrata 4200 mg/day reduced cerebral edema by >75% in 60% of patients vs 26% on placebo (P=0.023).
rct
Holtmeier 2011 Crohn's maintenance RCT
✓ PubMed
In a 52-week double-blind RCT across 22 German centers (82 randomized), Boswellia serrata extract failed to maintain remission of Crohn's disease better than placebo (~60% vs ~55%, P=0.85), though tolerability was good.
rct
Gupta 1998 bronchial asthma RCT
✓ PubMed
In a 6-week double-blind, placebo-controlled trial (n=80), Boswellia serrata gum resin 300 mg three times daily improved bronchial asthma (reduced dyspnoea/attacks, higher FEV1/FVC/PEFR, lower eosinophils) in 70% of patients vs 27% on placebo.
review
Singh 1996 boswellic acid toxicity review
✓ PubMed
A safety/toxicology evaluation found boswellic acids caused no mortality in rats and mice at oral and intraperitoneal doses up to 2 g/kg and no significant clinical, haematological, biochemical or pathological changes, concluding they are safe for clinical use.
Study
Standardized-extract trials
✓ Full text
AKBA-enriched extracts improved pain/function within days–weeks.
Mechanism
Mechanism
✓ PubMed
Boswellic acids inhibit 5-LOX and pro-inflammatory mediators.